Carcinoma, Non-Small-Cell Lung
Conditions
Brief summary
This is an observational retrospective study. The primary objective is to investigate the expression and potential prognostic role of Programmed Death Ligand 1 (PD-L1) in tumor samples from 350 patients with early stage treatment-naive non-small-cell lung cancer (NSCLC). Tissue samples were embedded in a tissue microarray. PD-L1 will be studied by immunohistochemistry using the SP263 antibody. Stained samples will be evaluated independently by two operators. A tumor will be defined as positive when = or \>50% of tumor cells express the ligand. The investigators will investigate the relationship between PD-L1 protein expression and overall survival and other clinical characteristics with appropriate statistical methods.
Interventions
OTHERimmunohistochemistry
Samples will be stained using the SP263 antibody clone against PD-L1
Sponsors
Fondazione Ricerca Traslazionale
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Early stage treatment-naive NSCLC
Exclusion criteria
* Received any pre-surgical treatment * no OS data available
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Expression | 15 days | The study will investigate PD-L1 protein expression by immunohistochemistry in tumor samples from early stage NSCLC |
| Prognostic value | 15 days | The correlation between PD-L1 protein expression by immunohistochemistry and overall survival will be studied |
Outcome results
None listed